Drug profile · INN
moxetumomab pasudotox-tdfk
LUMOXITI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
moxetumomab pasudotox-tdfk (LUMOXITI) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN moxetumomab pasudotox-tdfk
Brand LUMOXITI
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is moxetumomab pasudotox-tdfk?
moxetumomab pasudotox-tdfk (LUMOXITI) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for moxetumomab pasudotox-tdfk?
LUMOXITI is a marketed brand name for moxetumomab pasudotox-tdfk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of moxetumomab pasudotox-tdfk?
moxetumomab pasudotox-tdfk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.